- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04581369
Cirrhosis Medical Home (CMH)
Study Overview
Status
Conditions
Detailed Description
In the Cirrhosis Medical Home, a care coordinator, supported by an interdisciplinary clinical team, will deliver a personalized intervention guided by a set of innovative tools: (i) patient-centered care protocols, (ii) a mobile office, (iii) care coordination support software, and (iv) dynamic feedback measures.
The overall goal is to improve quality of life of patients discharged from the hospital with cirrhosis and to reduce acute health care utilization for patients with cirrhosis.
Additionally, up to 40 caregivers will be enrolled in the trial.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Indiana University Division of Gastroenterolgy and Hepatology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria for patients:
- Age ≥18 years
Cirrhosis based on:
- biopsy
- characteristic clinical, laboratory, and imaging findings
Decompensated cirrhosis as denoted by either:
- active ascites requiring paracentesis during hospitalization or
- active overt hepatic encephalopathy requiring lactulose during hospitalization
Poor quality of life as defined by:
- SF-36 Physical and/or Mental Component Summary scale <40 (1SD below the mean of healthy subjects)
- Discharged to home, skilled nursing facility, sub-acute rehabilitation care, or long-term acute care
- Able to be consented, either in person or through legally authorized representative
- Access to a telephone
Inclusion criteria for caregivers:
- Age ≥18 years
- Identified caregiver of patient
- Able to be consented, either in person or through legally authorized representative
- Access to a telephone
Exclusion Criteria for patients:
- Solid organ transplant of any organ
- Life expectancy of less than 6 months
- Anticipated liver transplant within 6 months
- History of dementing illnesses and other neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, or vascular dementia
- Unable to complete study questionnaire due to hearing loss
- Legally blind
- Pregnant or nursing
- Incarcerated
- Concurrent enrollment in a related interventional research study
Exclusion criteria for caregivers:
- Impaired cognitive function
- Unable to complete study questionnaire due to hearing loss
- Legally blind
- Incarcerated
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Direct Intervention
Initial Evaluation: Prior to discharge, the care coordinator will review the hospital discharge plan, obtain the approval of the patient's physicians to co-manage the patient's care, and schedule a visit with the patient at their place of discharge. Participants in this arm will receive direct interaction with a care coordinator to develop an individualized care plan. Frequent assessments, at least once every two weeks, will occur to continue to follow or to modify the care plan based on the needs of the patient. At the end of 6 months, all patients will be transitioned to receive full care by their primary care and specialty physicians and their participation in this study will be ended. |
The First Visit: The care coordinator will conduct a visit within 72 hours of hospital discharge to assess the patient's physical, cognitive, and psychological status, and will complete a needs assessment for both the patient and family caregiver. These measures will be used to guide the use of care protocols and development of the individualized care plan. The care plan will be developed with an emphasis on coordinating services with the patient's providers. The Second Visit: During the second visit, the coordinator will review the individualized care plan with both the patient and the family caregiver and will make revisions to the plan based on assessment outcomes. The 6-month Interaction Period: Approximately every 2 weeks, the coordinator will meet with the participant to revisit the care plan and to facilitate care. At the end of 6 months, all patients will be transitioned to receive full care by their primary care and specialty physicians.
Other Names:
|
Sham Comparator: Standard of Care
Prior to hospital discharge, the care coordinator will identify the primary care and/or hepatology provider of patients in the usual care group and will ensure follow up appointments at the time of hospital discharge.
The coordinator will compose and send a letter to the primary care and/or hepatology provider summarizing the patient's diagnosis, hospital course, discharge medications, and the plan of follow-up care.
If the patient does not already have a primary care or hepatology provider, the coordinator will work with the patient to identify a new provider.
Subjects in this group will receive no further intervention.
|
For participants randomized to this arm, a consultation with the care team will be arranged prior to hospital discharge.
Outcome measures will be obtained by blinded research staff from all enrolled subjects at baseline, 3 months, and 6 months.
This is the extent of interventions received for participants in this arm.
Other Names:
|
Placebo Comparator: Caregiver
The caregivers of people with cirrhosis will be enrolled in the study.
They will complete the assessments at baseline, 3 months and 6 months.
|
Caregivers of the participants will be assessed for caregiver burden at 3 time points.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Enrollment rate
Time Frame: 24 months
|
The proportion of screened patients/caregivers eligible, approached and enrolled will be calculated.
This is an internal assessment relating not to participants but to department specific metrics.
|
24 months
|
Number of participants who dropped out
Time Frame: 24 months
|
This is the proportion of enrolled participants (patients and caregivers) who drop out of the study before completion.
This is an internal assessment relating not to participants but to department specific metrics.
|
24 months
|
Number of participants with complete data
Time Frame: at end of study
|
Completeness of the data collection for enrolled subjects and reasons for incomplete data will be recorded.
This is an internal assessment relating not to participants but to department specific metrics.
|
at end of study
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Health Related Quality of Life: Medical Outcome Study Short Form (SF-36)
Time Frame: every 3 months for 6 months, at initial enrollment, 3 month, and 6 month visits
|
Assessment from the patient only through data collection from the Medical Outcome Study Short Form (SF-36) instrument.
This 36 item questionnaire has a minimum score of 36 with a maximum score of 180; a higher score generally correlates to poorer health.
|
every 3 months for 6 months, at initial enrollment, 3 month, and 6 month visits
|
Physical Performance
Time Frame: every 3 months for 6 months, at initial enrollment, 3 month, and 6 month visits
|
Assessment from the patient only through data collection from the Short Physical Performance Battery (SPPB) instrument.
|
every 3 months for 6 months, at initial enrollment, 3 month, and 6 month visits
|
Depression Symptoms
Time Frame: every 3 months for 6 months, at initial enrollment, 3 month, and 6 month visits
|
Assessment from patient only through data collection from the Patient Health Questionnaire-9 (PHQ-9) instrument.
This 9 item instrument that assesses depression and has a minimum score of 0 and a maximum score of 27; a lower score generally indicates no or a lesser amount of depression/anxiety than a higher score.
|
every 3 months for 6 months, at initial enrollment, 3 month, and 6 month visits
|
Anxiety Symptoms
Time Frame: every 3 months for 6 months, at initial enrollment, 3 month, and 6 month visits
|
Assessment from patient only through data collection from the Generalized Anxiety Disorder Scale (GAD-7) instrument.
This 7 item instrument that assess anxiety has a minimum score of 0 and a maximum score of 21, with a lower score indicating no or lesser anxiety than a higher score.
|
every 3 months for 6 months, at initial enrollment, 3 month, and 6 month visits
|
Cognitive assessment with 3D CAM (Confusion Assessment Method)
Time Frame: every 3 months for 6 months, at initial enrollment, 3 month, and 6 month visits
|
Assessment of overall levels of cognitive status, including hepatic encephalopathy
|
every 3 months for 6 months, at initial enrollment, 3 month, and 6 month visits
|
Cognitive assessment with PHES (The Psychometric Hepatic Encephalopathy Score)
Time Frame: every 3 months for 6 months, at initial enrollment, 3 month, and 6 month visits
|
Assessment of overall levels of cognitive status, including hepatic encephalopathy
|
every 3 months for 6 months, at initial enrollment, 3 month, and 6 month visits
|
Caregiver Burden
Time Frame: every 3 months for 6 months, at initial enrollment, 3 month, and 6 month visits
|
Assessment from caregivers only through data collection from the Zarit Burden Interview-12 (ZBI-12) instrument; a lower score is generally indicative of a lower amount caregiver fatigue or perception of burden; a higher score generally correlates to a greater level of caregiver fatigue/perceived burden.
|
every 3 months for 6 months, at initial enrollment, 3 month, and 6 month visits
|
CMH Interactions
Time Frame: every 2 weeks for 6 month enrollment of participant
|
During participation in this study, patients randomized to the Cirrhosis Medical Home Arm will meet with study staff, at least every 2 weeks for 6 months to assess overall health of the patient.
|
every 2 weeks for 6 month enrollment of participant
|
Acute Health Care Utilization
Time Frame: 6 months
|
This is an assessment of patient use of health care resources, including hospitalizations and Emergency room visits.
For the patient only, data will be gathered from the patient and medical record relating to the participant's emergency room visits and hospital admissions/inpatient stays during the course of their enrollment in the study.
|
6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Eric Orman, MD, Indiana University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CMH 2003678667
- R03DK122230 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cirrhosis, Liver
-
Postgraduate Institute of Medical Education and...Society for the Study of Liver Diseases, Chandigarh ( India )UnknownDecompensated Cirrhosis of LiverIndia
-
The Second Affiliated Hospital of Chongqing Medical...RecruitingFibrosis, Liver | Cirrhosis, LiverChina
-
SUUMC Central Military Hospital Dr Carol DavilaRecruiting
-
The Cleveland ClinicRecruiting
-
The Cleveland ClinicRecruitingCirrhosis, LiverUnited States
-
University of PittsburghNational Institute on Drug Abuse (NIDA)CompletedCirrhosis, LiverUnited States
-
Beth Israel Deaconess Medical CenterAmerican Association for the Study of Liver Diseases FoundationCompleted
-
Asian Institute of Gastroenterology, IndiaCompletedCirrhosis, LiverIndia
-
Sherief Abd-ElsalamUnknown
Clinical Trials on Care Coordinator Intervention for Direct Intervention Group
-
Uppsala UniversityCompletedBack Problems or Pain | Foot Problems or Pain | Shoulder Problems or PainSweden
-
Massachusetts General HospitalEnrolling by invitationHypertension | Cardiomyopathies | Hypertrophy, Left VentricularUnited States
-
Hospital de Clinicas de Porto AlegreUnknown
-
University of Alabama at BirminghamCompletedSickle Cell DiseaseUnited States
-
Shanghai Mental Health CenterCompleted
-
Harokopio UniversityCompleted
-
Fondazione IRCCS Ca' Granda, Ospedale Maggiore...CompletedStress, Physiological | Procedural Pain | Mother-Infant Interaction | Infant, NewbornItaly
-
Sociedad Española de Neumología y Cirugía TorácicaCompleted
-
Massachusetts General HospitalConquer Cancer FoundationCompletedAnxiety | Caregiver Burden | Malignant Glioma | Malignant Brain TumorUnited States
-
Pontificia Universidad Catolica de ChileComisión Nacional de Investigación Científica y TecnológicaCompletedChild Development | Mother-Child RelationsChile